Evidence map›Paper›PMID 36835999›Full record

ArticleJournal of clinical medicine2023

Perioperative Techniques for the Use of Botulinum Toxin in Overactive Bladder: Results of a Multinational Online Survey of Urogynecologists in Germany, Austria, and Switzerland.

Sören Lange, Marianne Koch, Rainer Lange, Heinrich Husslein, Wolfgang Umek, Barbara Bodner-Adler

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06250543 (Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA Efficacy and Safety in Women With Overactive Bladder and Urge Urinary Incontinence and the Value of Local Anesthesia for Pain Reduction), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06250543 phase4completednot on this map

Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA Efficacy and Safety in Women With Overactive Bladder and Urge Urinary Incontinence and the Value of Local Anesthesia for Pain Reduction

TypeinterventionalSponsorNiko KavcicRan2018 to 2022Enrolled64ConditionsOveractive BladderArmsAbobotulinumtoxinA 300 UNT, IncobotulinumtoxinA 100 UNT, Lidocain, placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sören LangeDepartment of General Gynecology and Gynecologic Oncology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-9066-7380
Marianne KochDepartment of General Gynecology and Gynecologic Oncology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-4748-2994
Rainer LangeDieGyn-Praxis, Lampertheim/Mainz/Bad Kreuznach, 55232 Alzey, Germany.
Heinrich HussleinDepartment of General Gynecology and Gynecologic Oncology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-0585-7444
Wolfgang UmekDepartment of General Gynecology and Gynecologic Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Barbara Bodner-AdlerDepartment of General Gynecology and Gynecologic Oncology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-2120-5550
Medical University of Vienna · ATOrthopädische Praxis · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and hypothesisBotulinum toxin (BoNT) is a widely used treatment for overactive bladder (OAB). Despite its common use, no standardized treatment regimen exists so far. The aim of this survey was to evaluate the variation in perioperative treatment strategies among members of the German-speaking urogynecologic societies. MATERIALS AND

methodsA clinical practice online survey was carried out between May 2021 and May 2022, and all members of the German, Swiss, and Austrian urogynecologic societies were invited to participate. Participants were grouped in two ways. First, they were grouped into (1) urogynecologists with board certification and (2) non-board-certified general obstetricians and gynecologists (OBGYNs). Second, we set a cut-off at 20 transurethral BoNT procedures per year to differentiate between (1) high- and (2) low-volume surgeons.

resultsOne hundred and six completed questionnaires were received. Our results demonstrated that BoNT is mostly used as a third-line treatment (93%,

conclusionsOur survey confirmed that BoNT is widely used by urogynecologists in the three German-speaking countries, but practice patterns vary widely, and no standardized method could be detected, despite interviewing urogynecologic experts. These results clearly demonstrate that there is a need for studies to define standardized treatment strategies for the best perioperative and surgical approach regarding the use of BoNT in patients with OAB.

Indexed as

botulinum toxinoveractive bladdersurvey

Identifiers

PMID36835999
PMCPMC9964329
OpenAlexW4320494051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.